Technical Analysis for ALIM - Alimera Sciences, Inc.

Grade Last Price % Change Price Change
grade F 0.8405 1.95% 0.02
ALIM closed down 1.2 percent on Thursday, January 17, 2019, on approximately normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical ALIM trend table...

Date Alert Name Type % Chg
Jan 17 20 DMA Resistance Bearish 2.50%
Jan 16 20 DMA Resistance Bearish 1.27%
Jan 16 180 Bearish Setup Bearish Swing Setup 1.27%
Jan 16 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.27%
Jan 16 Outside Day Range Expansion 1.27%
Jan 15 Narrow Range Bar Range Contraction -1.12%
Jan 15 NR7 Range Contraction -1.12%
Jan 15 Inside Day Range Contraction -1.12%
Jan 14 Fell Below 20 DMA Bearish 2.50%
Jan 14 Outside Day Range Expansion 2.50%

Older signals for ALIM ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Alimera Sciences, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina. The company's principal product candidate is ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye to a placement site that takes advantage of the eye's natural fluid dynamics to deliver the corticosteroid fluocinolone acetonide (FAc). The company has completed Phase III pivotal clinical trials for the treatment of DME; and in Phase II clinical trials for the treatment of the dry form of age-related macular degeneration and retinal vein occlusion. It has license agreements with pSivida US, Inc. for the development and sale of ILUVIEN; and Dainippon Sumitomo Pharma Co., Ltd. for the development, manufacture, and marketing of an injectable polymer tube implantable into an eye containing a mixture of a polymer and FAc. Alimera Sciences, Inc. was founded in 2003 and is based in Alpharetta, Georgia.
Is ALIM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 1.34
52 Week Low 0.718
Average Volume 88,793
200-Day Moving Average 0.967
50-Day Moving Average 0.9443
20-Day Moving Average 0.8424
10-Day Moving Average 0.861
Average True Range 0.0699
ADX 19.71
+DI 16.5763
-DI 21.3343
Chandelier Exit (Long, 3 ATRs ) 0.8003
Chandelier Exit (Short, 3 ATRs ) 0.9277
Upper Bollinger Band 0.9402
Lower Bollinger Band 0.7446
Percent B (%b) 0.39
BandWidth 23.219373
MACD Line -0.0264
MACD Signal Line -0.0294
MACD Histogram 0.003
Fundamentals Value
Market Cap 56.62 Million
Num Shares 69 Million
EPS -0.39
Price-to-Earnings (P/E) Ratio -2.10
Price-to-Sales 2.38
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.93
Resistance 3 (R3) 0.93 0.91 0.91
Resistance 2 (R2) 0.91 0.88 0.90 0.90
Resistance 1 (R1) 0.86 0.86 0.85 0.86 0.90
Pivot Point 0.84 0.84 0.83 0.83 0.84
Support 1 (S1) 0.79 0.81 0.78 0.79 0.74
Support 2 (S2) 0.77 0.79 0.76 0.74
Support 3 (S3) 0.72 0.77 0.73
Support 4 (S4) 0.72